Super Vilitra combines vardenafil (a PDE‑5 inhibitor) and dapoxetine (a fast-acting SSRI). It's designed for erectile dysfunction and premature ejaculation in men — because of this, it is not indicated for use during pregnancy or by women generally.
Specifically:
The manufacturer explicitly warns that pregnant women should not use Super Vilitra, as its active ingredients can transfer to the fetus and potentially cause complications, including increased bleeding during labor.
Similarly, lactating mothers are advised to avoid it, since components of the drug could pass into breast milk, potentially affecting the infant .
Looking at the individual drug profiles:
Vardenafil is classified as a category B drug in pregnancy, which means animal studies show no risk but there is limited human data. However, it’s still not approved or recommended for pregnant women.
Dapoxetine, an SSRI, has not been studied or approved for use in women at all, especially not during pregnancy.
Add your comment